



Scheduled End of the Intravenous Immune Globulin (IVIG) Demonstration

MLN Matters Number: SE17008

Related Change Request (CR) Number: N/A

Article Release Date: May 30, 2017

Effective Date: September 30, 2017



Related CR Transmittal Number: N/A

Implementation Date: N/A

PROVIDER TYPE AFFECTED

This MLN Matters Article is intended for suppliers submitting claims to Durable Medical Equipment Medicare Administrative Contractors (DME MACs) for Intravenous Immune Globulin (IVIG) drugs and services provided to beneficiaries under the Medicare IVIG Demonstration. The article is also intended for physicians who may treat patients with primary immune deficiency syndrome that use IVIG.

PROVIDER ACTION NEEDED

-  **STOP – Impact to you:**
This article is a reminder of the scheduled end date for the IVIG Demonstration.
-  **CAUTION – What you need to know:**
The IVIG Demonstration is a three-year demonstration that is scheduled to end September 30, 2017. **Since the demonstration ends on September 30, 2017, no payment will be made for the demonstration services (Q2052- IVIG demonstration, services/supplies) rendered after that date.** Claims submitted after that date for dates of service on/before September 30, 2017, will continue to be processed in accordance with the IVIG Demonstration guidelines. Please note that traditional Medicare fee for service will continue to pay for IVIG in the home but, once the demonstration ends, will no longer pay for the services and supplies to administer the drug unless the beneficiary is receiving covered Medicare home health services. Medicare will be notifying beneficiaries enrolled in the demonstration about the ending of payment for Q2052 as the ending of the demonstration may result in beneficiaries making alternative arrangements to receive their IVIG.

Since the demonstration ends on September 30, the last date that beneficiaries can submit an application for enrollment in the demonstration is August 15, 2017. This application must be received by the IVIG Demonstration Support Contractor,

Noridian, by this date either via fax or mail. Approved enrollments will be effective 9/1/17 allowing for IVIG services to be provided in the last month of the demonstration. Submission of an application does not guarantee that a beneficiary will be accepted to participate in the demonstration.



GO – What you need to do:

Make sure your billing staffs are aware of the end of the demonstration.

BACKGROUND

The Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012 authorized a three-year demonstration under Part B of Title XVIII of the Social Security Act to evaluate the benefits of providing payment for items and services needed for the in-home administration of IVIG for the treatment of Primary Immune Deficiency Disease (PIDD).

ADDITIONAL INFORMATION

For more information about the Medicare Intravenous Immune Globulin (IVIG) Demonstration, go to <https://innovation.cms.gov/initiatives/ivig/>. Additional information is also available on the Noridian IVIG website at <https://med.noridianmedicare.com/web/ivig>.

You may also want to review MLN Matters Article [MM9746](#), which specifies the IVIG Demonstration payment rate of \$354.60 for services rendered on or after January 1, 2017, through September 30, 2017, for code Q2052 (services, supplies, and accessories used in the home under the Medicare IVIG Demonstration).

If you have any questions, please contact your MAC at their toll-free number. That number is available at <https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/>. For questions specific to the IVIG demonstration, you may want to contact Noridian at 1-844-625-6284, Monday-Friday 8:30 a.m. – 4 p.m. CT.

Document History

Date of Change	Description
May 30, 2017	Initial article released

Disclaimer This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.